Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma

NCT04525209 | Unknown

• 1 other identifier: 2020-08-20
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

A large-scale, high-throughput, multi-dimensional comprehensive study of PDAC multiomics will be carried out. In this study, clinical specimens of resected PDAC collected by our research group from 2017 to 2019 will be selected as research objects.Tumor tissues and their adjacent non-tumor tissues from more than 200 PDAC patients are expected to be used for genome, transcriptome sequencing and mass spectrometry analysis of proteome and phosphorylated proteome.Combined with the data results of multiomics, bioinformatics analysis and network database information, we will clarify the relationship between multiomics of pancreatic cancer and established the new subtyping of pancreatic cancer proteome. A molecular landscape of the progression of pancreatic cancer at the genome-transcriptome-proteome level provides new therapeutic targets to improve the prognosis of this deadly disease.

Conditions

Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics

Outcome Measures

Primary Outcomes (1)

• Integrative Proteomic Characterization of PDAC

  The genome-transcriptome proteome level provides a molecular landscape of the progression of pancreatic cancer, providing new therapeutic targets to improve the prognosis of PDAC

  Two yeaers

Interventions

No intervention OTHER

No intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Chinese PDAC patients

You may qualify if:

• The diagnosis of pancreatic cancer was confirmed by histological examination or fine needle aspiration cytology;
• The tumor was graded according to THE WHO standard, and the tumor stage was graded according to the TNM stage;

You may not qualify if:

• There are few tissue specimens, only enough for clinical diagnosis;
• Patients are unwilling to conduct follow-up study;
• For the new diagnosed patient, radiotherapy or chemotherapy have been given in the previous three months;

Sponsors & Collaborators

• Ruijin Hospital: lead

Study Sites (1)

RUIJIN Hospital

Shanghai, Shanghai Municipality, 200025, China

Location

Related Publications (2)

• Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, Huang C, Li J, Dong X, Zhou Y, Liu Q, Ma L, Wang X, Zhou J, Liu Y, Boja E, Robles AI, Ma W, Wang P, Li Y, Ding L, Wen B, Zhang B, Rodriguez H, Gao D, Zhou H, Fan J. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell. 2019 Oct 3;179(2):561-577.e22. doi: 10.1016/j.cell.2019.08.052.

  PMID: 31585088 BACKGROUND

• Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu; Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007.

  PMID: 28810144 RESULT

Biospecimen

Retention: SAMPLES WITH DNA

PDAC tumor and Non-tumor DNA, RNA, protein

Study Officials

• Hao Chen, MD

  Ruijin Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Hao Chen, MD

CONTACT

13003135899; haochendr@126.com

Lingxi Jiang, Ph.D

CONTACT

13818826142; jlx12120@rjh.com.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chen Hao

Study Record Dates

• First Submitted: August 20, 2020
• First Posted: August 25, 2020
• Study Start: October 1, 2020
• Primary Completion: December 31, 2022
• Study Completion: December 31, 2022
• Last Updated: August 25, 2020

Record last verified: 2020-08

Locations

CN (1)